ClinicalTrials.gg
CompletedNCT00678392Updated Jan 9, 2019Results posted

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

A Phase 3 interventional study of Axitinib (AG-013736) and Sorafenib in Kidney Neoplasms, sponsored by Pfizer. Completed at 294 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
723
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing axitinib in Kidney Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Axitinib · Kidney Neoplasms.

Enrollment
3rd of 12
723 · median 54
Started
2008
the only one that year
Phase 3
4 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
5 of 12
Pfizer

Among the 12 studies testing axitinib in Kidney Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 2nd registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

3 of the 12 studies testing axitinib in Kidney Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing axitinib in Kidney Neoplasms, or all of them as a file.
02

Study summary

The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.

03

Conditions studied

  • Kidney Neoplasms

Browse trials for

Keywords

  • Axitinib in Second Line Treatment of Patients With Metastatic Renal Cell Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed renal cell cancer with a component of clear cell subtype, with
  • Evidence of
  • Must have failed one prior systemic regimen for metastatic renal cell cancer

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for renal cell cancer with more that one systemic therapy
  • Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
723 participants (actual)

Study arms

  • Experimental
    Axitinib

    Drug: Axitinib (AG-013736)

  • Active comparator
    Sorafenib

    Drug: Sorafenib

Interventions

  • axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing

  • sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: \>=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  2. Objective Response Rate (ORR)

    ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  3. Duration of Response (DR)

    DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  4. Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  5. Percentage of Participants With Adverse Events (AEs) by Severity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  6. Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  7. Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology

    Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  8. Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry

    Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  9. Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis

    Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: From initiation of treatment up to follow-up period (up to 3 years)

  10. Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score

    FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms.

    Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)

  11. Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score

    FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms.

    Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)

  12. Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health.

    Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)

  13. Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health.

    Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)

07

Results

Posted Mar 27, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib 5 mgSorafenib 400 mg
Started361362
Treated359355
Completed00
Not completed361362
Withdrew: Adverse event06
Withdrew: Death280269
Withdrew: Lost to follow-up1513
Withdrew: Objective progression or relapse38
Withdrew: Sponsor's decision12
Withdrew: Withdrawal by subject44
Withdrew: Randomized but not treated27
Withdrew: Other5653

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: \>=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsAxitinib 5 mgSorafenib 400 mg
Progression-Free Survival (PFS)6.7 (6.3 to 8.6)4.7 (4.6 to 5.6)
Statistical analysis
  • Axitinib 5 mg vs Sorafenib 400 mg · Log Rank · p = <0.0001 (P-value was obtained from 1-sided log rank test, stratified by eastern cooperative oncology group (ECOG) and prior treatment. One-sided log-rank test at 0.025 level of significance was used to compare PFS between the 2 treatment arms.) · Hazard ratio (hr): 0.665 · 95% CI 0.544 to 0.812
SecondaryOverall Survival (OS)

OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAxitinib 5 mgSorafenib 400 mg
Overall Survival (OS)20.1 (16.7 to 23.4)19.2 (17.5 to 22.3)
Statistical analysis
  • Axitinib 5 mg vs Sorafenib 400 mg · Log Rank · p = 0.3744 · Hazard ratio (hr): 0.969 · 95% CI 0.800 to 1.174P-value was obtained from a 1-sided log-rank test of treatment stratified by ECOG performance status and prior treatment.
SecondaryObjective Response Rate (ORR)

ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsAxitinib 5 mgSorafenib 400 mg
Objective Response Rate (ORR)19.4 (15.4 to 23.9)9.4 (6.6 to 12.9)
Statistical analysis
  • Axitinib 5 mg vs Sorafenib 400 mg · Cochran-Mantel-Haenszel · p = 0.0001 · Risk ratio (rr): 2.056 · 95% CI 1.408 to 3.003P-value was obtained from a 1-sided Cochran-Mantel-Haenszel test of treatment stratified by ECOG performance status and prior treatment.
SecondaryDuration of Response (DR)

DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Median · Months
Duration of Response (DR)
MonthsAxitinib 5 mgSorafenib 400 mg
Duration of Response (DR)11.0 (7.4 to NA)10.6 (8.8 to 11.5)
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participantsAxitinib 5 mgSorafenib 400 mg
AEs96.198.0
SAEs40.735.8
SecondaryPercentage of Participants With Adverse Events (AEs) by Severity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) by Severity
Percentage of participantsAxitinib 5 mgSorafenib 400 mg
Grade 13.93.1
Grade 220.121.7
Grade 347.652.4
Grade 410.611.5
Grade 513.99.3
SecondaryPercentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participantsAxitinib 5 mgSorafenib 400 mg
AEs92.295.2
SAEs15.313.8
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Hematology

Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology
ParticipantsAxitinib 5 mgSorafenib 400 mg
Hemoglobin: Grade 1 (n =320, 316)93112
Hemoglobin: Grade 2 (n =320, 316)1941
Hemoglobin: Grade 3 (n =320, 316)111
Hemoglobin: Grade 4 (n =320, 316)01
Lymphocytes: Grade 1 (n =317, 309)77
Lymphocytes: Grade 2 (n =317, 309)8993
Lymphocytes: Grade 3 (n =317, 309)1011
Lymphocytes: Grade 4 (n =317, 309)00
Neutrophils: Grade 1 (n =316, 308)1320
Neutrophils: Grade 2 (n =316, 308)44
Neutrophils: Grade 3 (n =316, 308)22
Neutrophils: Grade 4 (n =316, 308)00
Platelets: Grade 1 (n =312, 310)4741
Platelets: Grade 2 (n =312, 310)03
Platelets: Grade 3 (n =312, 310)10
Platelets: Grade 4 (n =312, 310)00
White Blood Cells: Grade 1 (n =320, 315)3236
White Blood Cells: Grade 2 (n =320, 315)412
White Blood Cells: Grade 3 (n =320, 315)01
White Blood Cells: Grade 4 (n =320, 315)00
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry

Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry
ParticipantsAxitinib 5 mgSorafenib 400 mg
Alanine aminotransferase: Grade 1 (n =331, 313)6557
Alanine aminotransferase: Grade 2 (n =331, 313)86
Alanine aminotransferase: Grade 3 (n =331, 313)12
Alanine aminotransferase: Grade 4 (n =331, 313)03
Alkaline phosphatase: Grade 1 (n =336, 319)8892
Alkaline phosphatase: Grade 2 (n =336, 319)815
Alkaline phosphatase: Grade 3 (n =336, 319)43
Alkaline phosphatase: Grade 4 (n =336, 319)00
Amylase: Grade 1 (n =338, 319)6476
Amylase: Grade 2 (n =338, 319)1221
Amylase: Grade 3 (n =338, 319)76
Amylase: Grade 4 (n =338, 319)01
Aspartate aminotransferase: Grade 1 (n =331, 311)5967
Aspartate aminotransferase: Grade 2 (n =331, 311)57
Aspartate aminotransferase: Grade 3 (n =331, 311)14
Aspartate aminotransferase: Grade 4 (n =331, 311)00
Bicarbonate: Grade 1 (n =314, 291)127115
Bicarbonate: Grade 2 (n =314, 291)1110
Bicarbonate: Grade 3 (n =314, 291)00
Bicarbonate: Grade 4 (n =314, 291)10
Bilirubin: Grade 1 (n =336, 318)1612
Bilirubin: Grade 2 (n =336, 318)82
Bilirubin: Grade 3 (n =336, 318)11
Bilirubin: Grade 4 (n =336, 318)00
Creatinine: Grade 1 (n =336, 318)155121
Creatinine: Grade 2 (n =336, 318)309
Creatinine: Grade 3 (n =336, 318)01
Creatinine: Grade 4 (n =336, 318)00
Hypercalcemia: Grade 1 (n =336, 319)9222
Hypercalcemia: Grade 2 (n =336, 319)81
Hypercalcemia: Grade 3 (n =336, 319)10
Hypercalcemia: Grade 4 (n =336, 319)00
Hyperglycemia: Grade 1 (n =336, 319)4128
Hyperglycemia: Grade 2 (n =336, 319)4537
Hyperglycemia: Grade 3 (n =336, 319)77
Hyperglycemia: Grade 4 (n =336, 319)00
Hyperkalemia: Grade 1 (n =333, 314)00
Hyperkalemia: Grade 2 (n =333, 314)4222
Hyperkalemia: Grade 3 (n =333, 314)98
Hyperkalemia: Grade 4 (n =333, 314)00
Hypernatremia: Grade 1 (n =338, 319)3423
Hypernatremia: Grade 2 (n =338, 319)1914
Hypernatremia: Grade 3 (n =338, 319)31
Hypernatremia: Grade 4 (n =338, 319)02
Hypoalbuminemia: Grade 1 (n =337, 319)3725
Hypoalbuminemia: Grade 2 (n =337, 319)1131
Hypoalbuminemia: Grade 3 (n =337, 319)12
Hypoalbuminemia: Grade 4 (n =337, 319)00
Hypocalcemia: Grade 1 (n =336, 319)2567
Hypocalcemia: Grade 2 (n =336, 319)418
Hypocalcemia: Grade 3 (n =336, 319)22
Hypocalcemia: Grade 4 (n =336, 319)12
Hypoglycemia: Grade 1 (n =336, 319)239
Hypoglycemia: Grade 2 (n =336, 319)1216
Hypoglycemia: Grade 3 (n =336, 319)11
Hypoglycemia: Grade 4 (n =336, 319)00
Hypokalemia: Grade 1 (n =333, 314)2221
Hypokalemia: Grade 2 (n =333, 314)00
Hypokalemia: Grade 3 (n =333, 314)05
Hypokalemia: Grade 4 (n =333, 314)00
Hyponatremia: Grade 1 (n =338, 319)3327
Hyponatremia: Grade 2 (n =338, 319)00
Hyponatremia: Grade 3 (n =338, 319)116
Hyponatremia: Grade 4 (n =338, 319)11
Hypophosphatemia: Grade 1 (n =336, 318)48
Hypophosphatemia: Grade 2 (n =336, 318)3399
Hypophosphatemia: Grade 3 (n =336, 318)651
Hypophosphatemia: Grade 4 (n =336, 318)00
Lipase: Grade 1 (n =338, 319)5376
Lipase: Grade 2 (n =338, 319)2225
Lipase: Grade 3 (n =338, 319)1440
Lipase: Grade 4 (n =338, 319)27
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis

Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
From initiation of treatment up to follow-up period (up to 3 years)
Reported as:
Number · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis
ParticipantsAxitinib 5 mgSorafenib 400 mg
Urine blood/ hemoglobin: Grade 1 (n =304, 272)4535
Urine blood/ hemoglobin: Grade 2 (n =304, 272)10
Urine blood/ hemoglobin: Grade 3 (n =304, 272)00
Urine blood/ hemoglobin: Grade 4 (n =304, 272)00
Urine glucose: Grade 1 (n =322, 286)1213
Urine glucose: Grade 2 (n =322, 286)03
Urine glucose: Grade 3 (n =322, 286)00
Urine glucose: Grade 4 (n =322, 286)11
Urine protein: Grade 1 (n =326, 289)10591
Urine protein: Grade 2 (n =326, 289)3127
Urine protein: Grade 3 (n =326, 289)2721
Urine protein: Grade 4 (n =326, 289)97
SecondaryFunctional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score

FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms.

Time frame:
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Reported as:
Mean · Units on a scale
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score
Units on a scaleAxitinib 5 mgSorafenib 400 mg
Baseline (n =346, 342)43.199 ± 8.41643.339 ± 8.162
Cycle 2/Day1 (n =319, 296)42.351 ± 8.30541.668 ± 7.696
Cycle 3/Day1 (n =279, 246)42.590 ± 7.72942.424 ± 7.888
Cycle 4/Day1 (n =257, 221)42.791 ± 8.18043.424 ± 7.345
Cycle 5/Day1 (n =238, 203)42.968 ± 8.15242.907 ± 7.255
Cycle 6/Day1 (n =213, 179)42.949 ± 7.84243.057 ± 7.724
Cycle 7/Day1 (n =206, 158)42.747 ± 7.62143.578 ± 7.621
Cycle 8/Day1 (n =177, 136)43.580 ± 7.57844.074 ± 7.757
Cycle 9/Day1 (n =163, 118)43.191 ± 8.30044.518 ± 6.511
Cycle 10/Day1 (n =146, 96)43.312 ± 8.56444.771 ± 7.155
Cycle 11/Day1 (n =122, 85)44.119 ± 8.30644.438 ± 7.388
Cycle 12/Day1 (n =110, 70)44.517 ± 8.21244.357 ± 7.247
Cycle 13/Day1 (n =92, 58)44.492 ± 7.97245.261 ± 7.840
Cycle 14/Day1 (n =81, 54)44.485 ± 8.20444.898 ± 7.495
Cycle 15/Day1 (n =61, 38)45.291 ± 7.09545.053 ± 6.682
Cycle 16/Day1 (n =52, 34)45.217 ± 7.65644.445 ± 7.160
Cycle 17/Day1 (n =47, 28)45.242 ± 7.34444.438 ± 7.683
Cycle 18/Day1 (n =36, 22)44.861 ± 7.76944.182 ± 7.228
Cycle 19/Day1 (n =29, 14)45.379 ± 6.66245.026 ± 7.705
Cycle 20/Day1 (n =20, 12)47.050 ± 5.37544.780 ± 6.689
Cycle 21/Day1 (n =15, 7)45.850 ± 5.20944.494 ± 6.153
End of treatment (n=163, 191)38.328 ± 9.47238.457 ± 8.787
Follow up (n =80, 110)41.919 ± 8.31840.028 ± 9.048
SecondaryFunctional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score

FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms.

Time frame:
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Reported as:
Mean · Units on a scale
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score
Units on a scaleAxitinib 5 mgSorafenib 400 mg
Baseline (n =346, 341)28.874 ± 5.18728.975 ± 5.193
Cycle 2/Day1 (n =319, 295)28.211 ± 4.92028.399 ± 5.064
Cycle 3/Day1 (n =279, 244)28.640 ± 4.83728.640 ± 4.868
Cycle 4/Day1 (n =257, 220)28.822 ± 4.95229.130 ± 4.322
Cycle 5/Day1 (n =238, 202)28.869 ± 4.88029.007 ± 4.379
Cycle 6/Day1 (n =213, 178)29.159 ± 4.46229.098 ± 4.697
Cycle 7/Day1 (n =206, 157)29.042 ± 4.58129.361 ± 4.558
Cycle 8/Day1 (n =177, 135)29.520 ± 4.34629.619 ± 4.386
Cycle 9/Day1 (n =163, 117)29.194 ± 4.93729.884 ± 3.838
Cycle 10/Day1 (n =146, 96)29.343 ± 4.90729.604 ± 3.959
Cycle 11/Day1 (n =122, 85)29.762 ± 4.94329.366 ± 4.404
Cycle 12/Day1 (n =110, 70)29.764 ± 4.50729.257 ± 4.299
Cycle 13/Day1 (n =92, 58)29.594 ± 4.20529.666 ± 4.710
Cycle 14/Day1 (n =81, 54)29.711 ± 4.31329.820 ± 4.333
Cycle 15/Day1 (n =61, 38)30.324 ± 3.58229.500 ± 3.454
Cycle 16/Day1 (n =52, 34)30.430 ± 3.44329.474 ± 4.146
Cycle 17/Day1 (n =47, 28)30.551 ± 3.33128.737 ± 4.930
Cycle 18/Day1 (n =36, 22)30.194 ± 3.99229.045 ± 4.520
Cycle 19/Day1 (n =29, 14)30.130 ± 3.63629.286 ± 4.795
Cycle 20/Day1 (n =20, 12)31.300 ± 2.73629.250 ± 4.025
Cycle 21/Day1 (n =15, 7)31.067 ± 3.17330.143 ± 4.100
End of Treatment (n =163, 191)26.288 ± 5.80626.517 ± 5.614
Follow up (n =80, 110)28.263 ± 4.80227.516 ± 5.577
SecondaryEuro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health.

Time frame:
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Reported as:
Mean · Units on a scale
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score
Units on a scaleAxitinib 5 mgSorafenib 400 mg
Baseline (n =347, 341)0.732 ± 0.2750.731 ± 0.257
Cycle 2/Day1 (n =326, 307)0.716 ± 0.2670.696 ± 0.237
Cycle 3/Day1 (n =287, 248)0.722 ± 0.2430.709 ± 0.239
Cycle 4/Day1 (n =262, 226)0.730 ± 0.2360.716 ± 0.248
Cycle 5/Day1 (n =244, 207)0.730 ± 0.2370.711 ± 0.243
Cycle 6/Day1 (n =221, 178)0.734 ± 0.2300.704 ± 0.246
Cycle 7/Day1 (n =213, 163)0.718 ± 0.2670.728 ± 0.228
Cycle 8/Day1 (n =181, 136)0.756 ± 0.2360.702 ± 0.259
Cycle 9/Day1 (n =169, 120)0.760 ± 0.2270.730 ± 0.229
Cycle 10/Day1 (n =151, 98)0.734 ± 0.2430.730 ± 0.233
Cycle 11/Day1 (n =126, 87)0.764 ± 0.2350.724 ± 0.250
Cycle 12/Day1 (n =110, 73)0.744 ± 0.2440.734 ± 0.232
Cycle 13/Day1 (n =96, 61)0.760 ± 0.2110.753 ± 0.232
Cycle 14/Day1 (n =80, 57)0.723 ± 0.2390.752 ± 0.211
Cycle 15/Day1 (n =63, 41)0.730 ± 0.2550.758 ± 0.191
Cycle 16/Day1 (n =54, 37)0.749 ± 0.2200.785 ± 0.158
Cycle 17/Day1 (n =48, 29)0.779 ± 0.1860.764 ± 0.193
Cycle 18/Day1 (n =37, 20)0.755 ± 0.2040.755 ± 0.208
Cycle 19/Day1 (n =29, 14)0.734 ± 0.2530.804 ± 0.184
Cycle 20/Day1 (n =21, 12)0.794 ± 0.2200.771 ± 0.182
Cycle 21/Day1 (n =16, 7)0.700 ± 0.2730.771 ± 0.182
End of Treatment (n =169, 196)0.608 ± 0.3160.612 ± 0.310
Follow up (n =76, 106)0.682 ± 0.2940.666 ± 0.295
SecondaryEuro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health.

Time frame:
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Reported as:
Mean · Units on a scale
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)
Units on a scaleAxitinib 5 mgSorafenib 400 mg
Baseline (n =341, 339)70.560 ± 19.18770.351 ± 17.403
Cycle 2/Day1 (n =317, 302)69.003 ± 20.19567.606 ± 18.265
Cycle 3/Day1 (n =280, 250)69.843 ± 17.92769.712 ± 18.429
Cycle 4/Day1 (n =261, 224)69.180 ± 18.63670.759 ± 17.189
Cycle 5/Day1 (n =244, 205)69.705 ± 18.33071.888 ± 16.999
Cycle 6/Day1 (n =220, 178)69.900 ± 18.16871.365 ± 17.019
Cycle 7/Day1 (n =209, 163)69.919 ± 18.06372.282 ± 17.521
Cycle 8/Day1 (n =180, 139)70.756 ± 19.18371.475 ± 18.523
Cycle 9/Day1 (n =168, 121)70.667 ± 18.55673.380 ± 17.473
Cycle 10/Day1 (n =151, 98)70.629 ± 18.68075.102 ± 14.854
Cycle 11/Day1 (n =126, 87)72.103 ± 18.06474.586 ± 15.161
Cycle 12/Day1 (n =111, 73)71.730 ± 17.27673.959 ± 15.852
Cycle 13/Day1 (n =94, 61)70.723 ± 19.14775.693 ± 14.571
Cycle 14/Day1 (n =81, 58)69.420 ± 20.28675.362 ± 15.875
Cycle 15/Day1 (n =62, 42)73.016 ± 15.32575.357 ± 15.368
Cycle 16/Day1 (n =52, 37)70.269 ± 19.27273.676 ± 15.699
Cycle 17/Day1 (n =48, 30)71.375 ± 17.84073.767 ± 16.298
Cycle 18/Day1 (n =37, 23)70.459 ± 18.85373.870 ± 16.904
Cycle 19/Day1 (n =29, 14)71.034 ± 16.96370.571 ± 17.956
Cycle 20/Day1 (n =21, 12)73.143 ± 15.34766.917 ± 17.758
Cycle 21/Day1 (n =16, 7)74.563 ± 16.05464.714 ± 16.183
End of Treatment (n =166, 197)61.759 ± 21.66861.690 ± 20.973
Follow up (n =76, 109)64.382 ± 21.39266.037 ± 19.754

Adverse events

Collected over From initiation of treatment up to follow-up period (up to 3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib 5 mg—146/359 (40.7%)337/359 (93.9%)
Sorafenib 400 mg—127/355 (35.8%)346/355 (97.5%)
Most frequent serious events
Showing 10 of 214
Most frequent serious events
EventAxitinib 5 mgSorafenib 400 mg
Disease progressionGeneral disorders32/35918/355
DehydrationMetabolism and nutrition disorders10/3591/355
AnaemiaBlood and lymphatic system disorders0/3598/355
DiarrhoeaGastrointestinal disorders8/3595/355
PyrexiaGeneral disorders7/3595/355
DyspnoeaRespiratory, thoracic and mediastinal disorders7/3593/355
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/3591/355
DeathGeneral disorders3/3596/355
Myocardial infarctionCardiac disorders6/3594/355
Gastrointestinal haemorrhageGastrointestinal disorders0/3595/355
Most frequent other events
Showing 10 of 50
Most frequent other events
EventAxitinib 5 mgSorafenib 400 mg
DiarrhoeaGastrointestinal disorders208/359195/355
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders100/359183/355
HypertensionVascular disorders156/359107/355
FatigueGeneral disorders151/359122/355
Decreased appetiteMetabolism and nutrition disorders140/359112/355
NauseaGastrointestinal disorders128/35984/355
AlopeciaSkin and subcutaneous tissue disorders18/359122/355
DysphoniaRespiratory, thoracic and mediastinal disorders116/35949/355
Weight decreasedInvestigations111/35983/355
RashSkin and subcutaneous tissue disorders53/359109/355

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or receive a different drug from that to which they were randomized.

Age, Customized
Age, Customized(Participants)Axitinib 5 mgSorafenib 400 mgTotal
Less than (<) 65 years238238476
Greater than or equal to (>=) 65 years123124247
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib 5 mgSorafenib 400 mgTotal
Female96104200
Male265258523
08

Study locations

294 sites
  • East Valley Hematology and Oncology Medical Group
    Burbank, California 91505, United States
  • Maurice Berkowtiz, MD
    Burbank, California 91505, United States
  • Agajanian Institute of Oncology and Hematology
    Downey, California 90241, United States
  • Los Angeles Hematology/Oncology Medical Group
    Glendale, California 91206, United States
  • Los Angeles Hematology/Oncology Medical Group
    Los Angeles, California 90017, United States
  • LAC-USC Medical Center
    Los Angeles, California 90033, United States
  • USC Norris Cancer Hospital and Clinics
    Los Angeles, California 90033, United States
  • Kenmar Research Institute
    Los Angeles, California 90057, United States
  • Metropolitan Hematology/Oncology Medical Group
    Los Angeles, California 90057, United States
  • Ronald Regan UCLA Medical Center
    Los Angeles, California 90095, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Agajanian Institute of Oncology and Hematology
    Montebello, California 90640, United States
  • Brian LeBerthon, MD, A Medical Corporation
    West Covina, California 91790, United States
  • Agajanian Institute of Oncology and Hematology
    Whittier, California 90606, United States
  • Rocky Mountain Cancer Centers
    Aurora, Colorado 80012, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • University of Colorado Denver: Division of Medical Oncology
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado 80909, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80220, United States
  • Rocky Mountain Cancer Centers
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer Centers
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers
    Parker, Colorado 80138, United States
  • Rocky Mountain Cancer Centers
    Thornton, Colorado 80260, United States
  • Georgetown University Hospital, Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists
    Bonita Springs, Florida 34135, United States
  • Florida Cancer Specialists
    Bradenton, Florida 34209, United States
  • Florida Cancer Specialists
    Cape Coral, Florida 33914, United States
  • Florida Cancer Specialists
    Cape Coral, Florida 33990, United States
  • University of Miami Sylvester at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • Florida Cancer Specialists
    Englewood, Florida 34223, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33908, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • University of Miami Hospital and Clinics
    Miami, Florida 33136, United States
  • Florida Cancer Specialists
    Naples, Florida 34102, United States
  • Florida Cancer Specialists
    Naples, Florida 34119, United States
  • M.D. Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Orlando Regional Medical Center
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists
    Venice, Florida 34285, United States
  • Florida Cancer Specialists
    Venice, Florida 34292, United States
  • Peachtree Hematology-Oncology Consultants, P.C.
    Atlanta, Georgia 30318, United States
  • Chattanooga Oncology and Hematology Associates, PC
    Ringgold, Georgia 30736, United States
  • Mountain States Tumor Institute
    Boise, Idaho 83712, United States
  • Mountain States Tumor Institute
    Fruitland, Idaho 83619, United States
  • Mountain States Tumor Institute
    Meridian, Idaho 83642, United States
  • Mountain States Tumor Institute
    Nampa, Idaho 83686, United States
  • Mountain States Tumor Institute
    Twin Falls, Idaho 83301, United States
  • Loyola University Chicago Cardinal Bernardin Cancer Center
    Maywood, Illinois 60153, United States
  • Cental Indiana Cancer Centers
    Carmel, Indiana 46032, United States
  • Central Indiana Cancer Centers
    Fishers, Indiana 46037, United States
  • Cental Indiana Cancer Centers
    Greenfield, Indiana 46140, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46219, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109-5948, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Weisberg Cancer Treatment Center
    Farmington Hills, Michigan 48334, United States
  • University of Minnesota Medical Center Fairview
    Minneapolis, Minnesota 55455, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • St. John's Mercy Medical Center
    Saint Louis, Missouri 63141, United States
  • St. John's Mercy, David C. Pratt Cancer Center
    Saint Louis, Missouri 63141, United States
  • St. John's Mercy Medical Center
    Washington, Missouri 63090, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • The Cancer Center at Hackensack University Medical Center - The Hillcrest Building
    Hackensack, New Jersey 07601, United States
  • The Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center
    Bronx, New York 10466, United States
  • Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc.
    Oneida, New York 13421, United States
  • Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc.
    Oswego, New York 13126, United States
  • Suny Upstate Medical University
    Syracuse, New York 13210-2306, United States
  • Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc
    Syracuse, New York 13210, United States
  • Raleigh Hematology Oncology Associates, DBA
    Cary, North Carolina 27518, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Investigational Chemotherapy Services
    Durham, North Carolina 27710, United States
  • Albermarie Hospitals
    Elizabeth City, North Carolina 27909, United States
  • Virginia Oncology Associates
    Elizabeth City, North Carolina 27909, United States
  • Raleigh Hematology Oncology Associates, P.C.
    Raleigh, North Carolina 27607, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    Columbus, Ohio 43210, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • James Care in Kenny
    Columbus, Ohio 43211, United States
  • Monarch
    Mayfield Heights, Ohio 44124, United States
  • Lake University - Ireland Cancer Center (LUICC)
    Mentor, Ohio 44060, United States

Showing the first 100 of 294 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Murphy DA, Rini BI, Escudier B, Motzer RJ, Wang P, Li S, Williams JA, Tarazi JC, Martini JF. Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. Future Oncol. 2020 Jun;16(17):1199-1210. doi: 10.2217/fon-2020-0212. Epub 2020 May 4. PubMed 32363929 ↗
  • Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703. doi: 10.1016/j.clgc.2019.03.017. Epub 2019 Apr 1. PubMed 31072748 ↗
  • de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21. PubMed 28410911 ↗
  • Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26. PubMed 27238653 ↗
  • Grunwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7. PubMed 25577718 ↗
  • Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13. PubMed 24823696 ↗
  • Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol. 2013 Jun;43(6):616-28. doi: 10.1093/jjco/hyt054. Epub 2013 Apr 28. PubMed 23630366 ↗
  • Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Erratum In: Lancet Oncol. 2013 Jun;14(7):e254. PubMed 23598172 ↗
  • Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, Rosbrook B, Kim S, Motzer R. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer. 2013 Apr 30;108(8):1571-8. doi: 10.1038/bjc.2013.145. Epub 2013 Apr 11. PubMed 23579211 ↗
  • Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Erratum In: Lancet. 2012 Nov 24;380(9856):1818. PubMed 22056247 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Aug 2010, 23 months.

Results were first posted in Mar 2012, 1 year 6 months after primary completion. A results delay was requested in Oct 2010.

Of 22 phase 3 interventional studies under Kidney Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 89. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2008
First posted
May 15, 2008
StartActual
Sep 3, 2008
Primary completionActual
Aug 31, 2010
CompletionActual
Feb 25, 2016
Results delay requested
Oct 2, 2010
Results first posted
Mar 27, 2012
Last update
Jan 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00678392
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 15, 2008
Start date
Sep 3, 2008
Primary completion
Aug 31, 2010
Completion
Feb 25, 2016
Results posted
Mar 27, 2012
Last update
Jan 9, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion